Quick Answer
Regencell Bioscience Holdings Ltd reported Net Income of -$3.58 million for fiscal year 2025.
Regencell Bioscience Holdings Ltd — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$3.58M +16.7% |
-$4.30M +26.7% |
-$5.87M +21.1% |
-$7.45M -452.9% |
-$1.35M -65.8% |
-$812.4K -107.8% |
| Diluted EPS | -$0.72 +17.2% |
-$0.87 +26.9% |
-$1.19 -105.2% |
-$0.58 -346.2% |
-$0.13 -62.5% |
-$0.08 |
| Total Assets | $5.76M -31.8% |
$8.44M -33.1% |
$12.62M -30.0% |
$18.02M +5197.6% |
$340.1K -33.8% |
$514.0K |
| Cash and Equivalents | — | — | — | $6.42M +10700.7% |
$59.4K -84.6% |
$387.0K +59.0% |
| Stockholders Equity | $4.86M -40.9% |
$8.22M -31.7% |
$12.03M -29.5% |
$17.07M +526.9% |
-$4.00M -50.8% |
-$2.65M -44.2% |
| R&D Expense | $948.3K -11.1% |
$1.07M -32.6% |
$1.58M -37.0% |
$2.51M +473.1% |
$438.3K +13.5% |
$386.2K +69.2% |
| Operating Income | -$3.77M +20.4% |
-$4.74M +24.5% |
-$6.27M +17.6% |
-$7.62M -451.5% |
-$1.38M -70.0% |
-$812.4K -107.8% |
| Shares Outstanding | 494.49M +0.0% |
494.49M +3700.0% |
13.01M +0.0% |
13.01M +30.1% |
10.00M +0.0% |
10.00M |
- Regencell Bioscience Holdings Ltd reported Net Income of -$3.58 million for fiscal year 2025.
- Regencell Bioscience Holdings Ltd showed an increase of +16.7% in Net Income compared to the prior fiscal year.
- Regencell Bioscience Holdings Ltd reported Diluted EPS of $0.72 per share (loss) for fiscal year 2025.
- Regencell Bioscience Holdings Ltd showed an increase of +17.2% in Diluted EPS compared to the prior fiscal year.
- Regencell Bioscience Holdings Ltd reported Total Assets of $5.76 million for fiscal year 2025.
- Regencell Bioscience Holdings Ltd showed a decrease of -31.8% in Total Assets compared to the prior fiscal year.
- Regencell Bioscience Holdings Ltd reported Cash and Equivalents of $6.42 million for fiscal year 2022.
- Regencell Bioscience Holdings Ltd showed an increase of +10700.7% in Cash and Equivalents compared to the prior fiscal year.
- Regencell Bioscience Holdings Ltd reported Stockholders Equity of $4.86 million for fiscal year 2025.
- Regencell Bioscience Holdings Ltd showed a decrease of -40.9% in Stockholders Equity compared to the prior fiscal year.
- Regencell Bioscience Holdings Ltd reported R&D Expense of $948.3 thousand for fiscal year 2025.
- Regencell Bioscience Holdings Ltd showed a decrease of -11.1% in R&D Expense compared to the prior fiscal year.
- Regencell Bioscience Holdings Ltd reported Operating Income of -$3.77 million for fiscal year 2025.
- Regencell Bioscience Holdings Ltd showed an increase of +20.4% in Operating Income compared to the prior fiscal year.
- Regencell Bioscience Holdings Ltd reported Shares Outstanding of 494.49 million shares for fiscal year 2025.
- Regencell Bioscience Holdings Ltd showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: